BioCryst Pharmaceuticals Net Income
| BCRX Stock | USD 6.76 0.04 0.59% |
As of the 17th of February 2026, BioCryst Pharmaceuticals shows the Standard Deviation of 2.69, mean deviation of 1.93, and Risk Adjusted Performance of (0.01). BioCryst Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
BioCryst Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.5166 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -80 M | -84 M | |
| Net Loss | -80 M | -84 M | |
| Net Loss | -222.4 M | -211.3 M | |
| Net Loss | (0.49) | (0.52) | |
| Net Income Per E B T | 0.92 | 0.97 |
BioCryst | Net Income | Build AI portfolio with BioCryst Stock |
The evolution of Net Income for BioCryst Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BioCryst Pharmaceuticals compares to historical norms and industry peers.
Latest BioCryst Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of BioCryst Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in BioCryst Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of BioCryst Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is BioCryst Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (88.88 M) | 10 Years Trend |
|
Net Income |
| Timeline |
BioCryst Net Income Regression Statistics
| Arithmetic Mean | (96,806,909) | |
| Coefficient Of Variation | (73.42) | |
| Mean Deviation | 55,275,123 | |
| Median | (79,992,900) | |
| Standard Deviation | 71,071,477 | |
| Sample Variance | 5051.2T | |
| Range | 240.2M | |
| R-Value | (0.62) | |
| Mean Square Error | 3284T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | (8,794,857) | |
| Total Sum of Squares | 80818.5T |
BioCryst Net Income History
Other Fundumenentals of BioCryst Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
BioCryst Pharmaceuticals Net Income component correlations
BioCryst Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for BioCryst Pharmaceuticals is extremely important. It helps to project a fair market value of BioCryst Stock properly, considering its historical fundamentals such as Net Income. Since BioCryst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioCryst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioCryst Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. Projected growth potential of BioCryst fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive BioCryst Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.05) | Revenue Per Share | Quarterly Revenue Growth 0.361 | Return On Assets | Return On Equity |
Understanding BioCryst Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects BioCryst's accounting equity. The concept of intrinsic value - what BioCryst Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push BioCryst Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between BioCryst Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioCryst Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, BioCryst Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
BioCryst Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioCryst Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioCryst Pharmaceuticals.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in BioCryst Pharmaceuticals on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding BioCryst Pharmaceuticals or generate 0.0% return on investment in BioCryst Pharmaceuticals over 90 days. BioCryst Pharmaceuticals is related to or competes with Zymeworks Common, Ardelyx, Maze Therapeutics, Pharvaris, Spyre Therapeutics, Intellia Therapeutics, and Trevi Therapeutics. BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines More
BioCryst Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioCryst Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioCryst Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 16.75 | |||
| Value At Risk | (4.19) | |||
| Potential Upside | 4.43 |
BioCryst Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioCryst Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioCryst Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use BioCryst Pharmaceuticals historical prices to predict the future BioCryst Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.27) | |||
| Treynor Ratio | (0.11) |
BioCryst Pharmaceuticals February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 1.93 | |||
| Coefficient Of Variation | (4,468) | |||
| Standard Deviation | 2.69 | |||
| Variance | 7.22 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.27) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 16.75 | |||
| Value At Risk | (4.19) | |||
| Potential Upside | 4.43 | |||
| Skewness | 0.4715 | |||
| Kurtosis | 2.15 |
BioCryst Pharmaceuticals Backtested Returns
BioCryst Pharmaceuticals secures Sharpe Ratio (or Efficiency) of close to zero, which signifies that the company had a close to zero % return per unit of risk over the last 3 months. BioCryst Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioCryst Pharmaceuticals' Risk Adjusted Performance of (0.01), mean deviation of 1.93, and Standard Deviation of 2.69 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.65, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioCryst Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding BioCryst Pharmaceuticals is expected to be smaller as well. At this point, BioCryst Pharmaceuticals has a negative expected return of -0.0045%. Please make sure to confirm BioCryst Pharmaceuticals' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if BioCryst Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.72 |
Almost perfect reverse predictability
BioCryst Pharmaceuticals has almost perfect reverse predictability. Overlapping area represents the amount of predictability between BioCryst Pharmaceuticals time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioCryst Pharmaceuticals price movement. The serial correlation of -0.72 indicates that around 72.0% of current BioCryst Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.72 | |
| Spearman Rank Test | -0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 0.15 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
BioCryst Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, BioCryst Pharmaceuticals reported net income of (88.88 Million). This is 126.04% lower than that of the Biotechnology sector and 226.89% lower than that of the Health Care industry. The net income for all United States stocks is 115.57% higher than that of the company.
BioCryst Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioCryst Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics of similar companies.BioCryst Pharmaceuticals is currently under evaluation in net income category among its peers.
BioCryst Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioCryst Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioCryst Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
BioCryst Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in BioCryst Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of BioCryst Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioCryst Pharmaceuticals' value.| Shares | Two Sigma Investments Llc | 2025-06-30 | 4.3 M | Arrowstreet Capital Limited Partnership | 2025-06-30 | 4.3 M | Two Sigma Advisers, Llc | 2025-06-30 | 4.2 M | Rp Management, Llc | 2025-03-31 | 3.8 M | Assenagon Asset Management Sa | 2025-06-30 | 3.6 M | Nuveen, Llc | 2025-06-30 | 3.5 M | Goldman Sachs Group Inc | 2025-06-30 | 3.5 M | Bank Of America Corp | 2025-06-30 | 2.8 M | Fisher Asset Management, Llc | 2025-06-30 | 2.8 M | Blackrock Inc | 2025-06-30 | 21.4 M | Vanguard Group Inc | 2025-06-30 | 20.5 M |
BioCryst Fundamentals
| Return On Equity | -19.25 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 2.11 B | ||||
| Shares Outstanding | 248.04 M | ||||
| Shares Owned By Insiders | 1.32 % | ||||
| Shares Owned By Institutions | 82.11 % | ||||
| Number Of Shares Shorted | 39.45 M | ||||
| Price To Earning | (7.11) X | ||||
| Price To Book | 56.59 X | ||||
| Price To Sales | 2.80 X | ||||
| Revenue | 450.71 M | ||||
| Gross Profit | 410.45 M | ||||
| EBITDA | 12.81 M | ||||
| Net Income | (88.88 M) | ||||
| Cash And Equivalents | 417.48 M | ||||
| Cash Per Share | 2.24 X | ||||
| Total Debt | 841.42 M | ||||
| Debt To Equity | 2.40 % | ||||
| Current Ratio | 5.19 X | ||||
| Book Value Per Share | (1.84) X | ||||
| Cash Flow From Operations | (52.02 M) | ||||
| Short Ratio | 8.25 X | ||||
| Earnings Per Share | (0.05) X | ||||
| Price To Earnings To Growth | (0.28) X | ||||
| Target Price | 21.67 | ||||
| Number Of Employees | 580 | ||||
| Beta | 0.79 | ||||
| Market Capitalization | 1.68 B | ||||
| Total Asset | 490.42 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Working Capital | 261.58 M | ||||
| Current Asset | 65.99 M | ||||
| Current Liabilities | 64.45 M | ||||
| Net Asset | 490.42 M |
About BioCryst Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioCryst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.